Early Phase 1 N=4 High Frequency SARS for Neurogenic Bladder and Bowel Emptying
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI
Spinal Cord Injury · Constipation · Fecal Incontinence
Primary: Baseline Motility (Anorectal Sensation and Strength) Characteristics — 105; 34.4; 30; 77.9 mmHg
Phase 2 N=37 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
N/A N=2 Stimulation for Colonic Motility
Neurogenic Bowel Dysfunction
Primary: Compare Changes in Number of Interventions Used to Complete Bowel Routine, Including Electrical Rectal Stimulation (Treatment) Versus Mechanical Rectal Distension…
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
N/A N=55 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Urinary Incontinence
Primary: Change From Baseline in Anticholinergic Drug Use — 305.21; 199.77 Doses of Anticholinergic Drugs
N/A N=166 Neuromodulation for Accidental Bowel Leakage
Fecal Incontinence · Bowel Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -2.8; -3.3; -4.3; -4.1 units on a scale
N/A N=78 Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
Neurogenic Bladder · Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Willingness to Repeat Procedure — 9.16; 9.34; 9.73; 9.67 units on a scale — p=0.57
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
N/A N=31 Comparison of Motor and Sensory Response With Interstim Stimulation
Overactive Bladder · Urgency-Frequency
Primary: Percent of Symptoms With Improvement of Leaks Reported — 14.4; 19.8; 18.2 Percent change in leaks
Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
N/A N=8 Infracoccygeal Botox for Dyssynergia
Dyssynergic Defaecation · Evacuation Disorder · Anismus
Primary: The Rate of Identification of Puborectalis During Ultrasound Scan — 8 Participants
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
Phase 4 N=120 Sugammadex To IMprove Bowel Function
Bowel Dysfunction · Postoperative Complications · Neuromuscular Blockade
Primary: Gastric Emptying — 1120; 1130 log(ng*ml-1)*min — p=0.58
Phase 2 N=96 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .594 Adverse Events — p==0.219
Phase 1 N=13 Colonizing Neurogenic Bladders With Benign Flora
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
Phase 3 N=416 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes
N/A N=101 Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence
Constipation · Fecal Incontinence
Primary: Percentage of Patients Considering the Treatment a Success After 5 Years — 81.7; 87.3; 31.2; 91.7 percentage of success
Phase 3 N=21 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes
Phase 4 N=360 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
N/A N=16 Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation
Chronic Spinal Cord Injury · Neurogenic Bowel
Primary: Safety of Using TTNS at Home Daily as Indicated by Number of Adverse Events Recorded in Bladder Diary — 0 adverse events
Phase 3 N=144 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Urinary Incontinence · Multiple Sclerosis · Neurogenic Bladder
Primary: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes — 4.18; 4.32; -3.34; -1.10 Episodes
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 4 N=24 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
Detrusor Hyperreflexia
Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day
N/A N=72 Bowel Function After Minimally Invasive Urogynecologic Surgery
Functional Disorder of Intestine
Primary: Time to First Post-op Bowel Movement — 64; 77 hours
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…